MannKind Corporation - Common Stock (NQ:MNKD)

MannKind (NASDAQ:MNKD) Chief Executive Officer Mike Castagna said the company is advancing an inhaled version of nintedanib into a global Phase 2 study for idiopathic pulmonary fibrosis, or IPF,...

MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth ↗

October 20, 2026

Performance

52-Week Range 41.5% below 52-week high

3.810

2.2352W Low 6.5152W High

1 Week

3.231W Low 3.761W High

MannKind Corporation - Common Stock (MNKD) traded between $2.23 and $6.51 over the past 52 weeks and last traded at $3.81, 41.5% below its 52-week high. Over the past week it ranged between $3.23 and $3.76.

Past 12 Months

+11.1%

-0.3%

-3.8%

+33.2%

-32.0%

-30.5%

1W +$0.38

1M -$0.01

3M -$0.15

6M +$0.95

YTD -$1.79

1Y -$1.67

MNKD was -30.5% over the past year, +33.2% over six months, -32.0% year to date, +11.1% in the last week.

12 Months vs Market

MNKD

-30.5%

DIA

+11.5%

SPY

+11.7%

QQQ

+8.9%

IWM

+16.0%

Over the past 12 months MNKD returned -30.5% versus DIA (Dow) +11.5%, SPY (S&P 500) +11.7%, QQQ (Nasdaq 100) +8.9% and IWM (Russell 2000) +16.0%.

Volume & Liquidity 0.01× 3-mo avg

Today 42,158 3-mo avg 4.2M

3.1M

3.5M

4.2M

5.0M

YTD

5.1M

4.9M

MNKD most recently traded 42,158 shares against a 3-month average daily volume of 4.2M.

More News

MannKind to Participate in the Chardan Healthcare Conference

October 14, 2026

From MannKind

MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)

October 09, 2026

From MannKind

MannKind (NASDAQ:MNKD) Falls as Q2 EPS Miss Overshadows In-Line Revenue ↗

August 05, 2026

Via Chartmill

MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum ↗

September 17, 2026

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

September 09, 2026

From MannKind

MannKind to Present at Upcoming Investor Conferences

September 02, 2026

From MannKind

MannKind Q2 Earnings Call Highlights ↗

August 05, 2026

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

August 05, 2026

From MannKind

MannKind’s Inhaled IPF Drug Clears Phase 1b Safety Hurdle, Phase 2 Underway ↗

July 29, 2026

MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

July 29, 2026

From MannKind

MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026

July 28, 2026

From MannKind

MannKind Wins FDA Approval for Furoscix ReadyFlow, Secures $50M PIPE ↗

July 24, 2026

MannKind Announces $50 Million Private Placement

July 24, 2026

From MannKind

MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease

July 24, 2026

From MannKind

What This MannKind Filing Reveals About Three Years of Underperformance ↗

July 20, 2026

What This MannKind Director Sale Signals With $32.7 Million in Quarterly Royalties Revenue Potentially at Risk ↗

July 20, 2026

What This MannKind Sale Signals With Tyvaso Royalties at $32.7 Million ↗

July 20, 2026

Why This MannKind Insider Stock Sale Matters Less Than a 9% Royalty at Risk ↗

July 20, 2026

Is MannKind a Stock to Sell After Its CEO Let Go of 363,200 Shares? ↗

July 19, 2026

MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D

June 23, 2026

From MannKind

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

June 05, 2026

From MannKind

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

June 03, 2026

From MannKind

MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market ↗

May 30, 2026